Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

Who­ev­er is tak­ing Ote­zla off Bris­tol-My­ers Squibb’s hands will have one more rev­enue stream to boast.

The drug — a ris­ing star in Cel­gene’s pipeline that gen­er­at­ed glob­al sales of $1.6 bil­lion last year — is now OK’d to treat oral ul­cers as­so­ci­at­ed with Be­hçet’s dis­ease, a com­mon symp­tom for a rare in­flam­ma­to­ry dis­or­der. This marks the third FDA ap­proval for the PDE4 in­hibitor since 2014, when it was green­light­ed for plaque pso­ri­a­sis and pso­ri­at­ic arthri­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA